Passion for cancer research and clinical oncology. Radiation Oncology at MSKCC. #CancerOutcomes #NeuroOnc #CancerMetabolism
Joined April 2020
- Tweets1.1K
- Following545
- Followers470
- Likes4.9K
Pinned Tweet
Very proud and fortunate to be mentored by Dr. Neugut, who won the @columbiacancer Mentor of the Year Award
Pleasure to have a colleague notify me today that our article is in print in the @JCO_ASCO
"Prognostic and Predictive Effect of Age in Molecularly Defined Lower-Grade Gliomas"
ascopubs.org/doi/full/10.120…
1/n Virtually every RCT of CRT for LGG used age ≥40 yrs as inclusion. Every major guidelines still cites age as a high-risk factor for LGG
Connor Kinslow, MD retweeted
1/6:
I am excited to share our multi-institutional F-SHARP phase I/II trial, now published in @JCO_ASCO!
doi.org/10.1200/JCO-25-02730
There are limited prospective data defining the optimal management of intraprostatic radiorecurrence (IPR) after definitive RT for prostate cancer.
We asked:
1. Is dose-escalated focal salvage high dose rate brachytherapy safe and effective for IPR?
2. Can Decipher (@Veracyte) identify patients with higher risk of recurrence with salvage ReRT that may benefit from therapeutic intensification?
🧵👇
Connor Kinslow, MD retweeted
Fantastic work led by @dtbergman analyzing 3,893 patients treated with Linac SRS for brain mets. OS plateaus from 5-20 lesions & salvage WBRT is rare. Data support an SRS-first strategy over fixed lesion limits! doi.org/10.1093/noajnl/vdag2… @MSKCancerCenter @MSK_RadOnc
Connor Kinslow, MD retweeted
Excited to share our new paper out today in @NatureMetabolism! "Hyperglycosylation is a metabolic driver of Alzheimer’s disease"
*We bridged spatial metabolomics (MALDI-MSI glycomics + lipidomics + isotopic pulse-chase tracing) directly to experimental biochemistry (genetic knockdown of glycan enzymes + glucosamine supplementation in AD models) and real-world public health data (EHR analysis showing glucosamine use linked to faster MCI-to-AD progression and worse survival).
**Key takeaway: The AD brain shows conserved hyperglycosylation driven by ramped-up glycan biosynthesis — not just a byproduct, but a causal driver. Reducing it helps cognition; boosting it (e.g., via glucosamine) worsens outcomes.
***We applied cutting-edge spatial tech to functional validation and clinical translation.
Full open-access paper: nature.com/articles/s42255-0…
Huge thanks to the incredible team, collaborators (incl. Matt Gentry, Stefan Prokop, @ji0ngbi0n , Yi Guo, @lichenbiostat, Ralph Deberardinis & others), and the patients/families who make this work possible.
Connor Kinslow, MD retweeted
Excited to share our new paper with @Mitch_P and @Luke_Pike_MD @pike_lab!
Nearly 4,000 brain mets patients treated with linac-based SRS at MSK: contemporary survival outcomes, prognostic factors, and what happens next with salvage treatment. 🧵
doi.org/10.1093/noajnl/vdag2…
Connor Kinslow, MD retweeted
Microwave ablation versus stereotactic body radiotherapy for oligometastatic colorectal liver metastases (LAVA-CRLM): a prospective, randomised, phase II trial
thelancet.com/journals/lanep…
To those at @EANOassociation #EANO2026 please consider coming to my presentation at the high-impact selected abstracts session at 9a:
“Ki-67 proliferation index and prognosis in 1p19q-code letter oligodendrogliomas: analysis of two large US cohorts”
Connor Kinslow, MD retweeted
We have waited more than a decade for this: ROAM is presented in Rome #EANO2026! See the results of ROAM/EORTC-1308, now also published in @TheLancet!
@EANOassociation
thelancet.com/journals/lance…
Editorial,
“Mature results from EORTC 22033: Implications of inferior results with monotherapy for grade 2 gliomas”
published in @NeuroOnc
It’s an honor to write this editorial w/ Dr. Schiff
academic.oup.com/neuro-oncol…
